Pages that link to "Q43705801"

The following pages link to Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy (Q43705801):

Displaying 46 items.

• Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (Q22242395) (← links)
• Cholinesterase inhibitors for rarer dementias associated with neurological conditions (Q24187428) (← links)
• Cholinesterase inhibitors for neurological conditions associated with rarer dementias (Q24201472) (← links)
• The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier) (Q28485924) (← links)
• Progressive supranuclear palsy: where are we now? (Q30810295) (← links)
• Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial (Q34031302) (← links)
• Current and future treatments in progressive supranuclear palsy (Q34506364) (← links)
• Progress in clinical neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors. (Q35015451) (← links)
• Cholinesterase Inhibitors in Non-Alzheimer Dementias (Q35582108) (← links)
• Pharmacologic treatment of adolescent and child schizophrenia (Q36107249) (← links)
• The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases (Q36143785) (← links)
• Toward future therapies in progressive supranuclear palsy. (Q36224235) (← links)
• Cognitive and behavioral aspects of PSP since Steele, Richardson and Olszewski's description of PSP 40 years ago and Albert's delineation of the subcortical dementia 30 years ago. (Q36225061) (← links)
• Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors (Q36772321) (← links)
• Treatment of frontotemporal dementia (Q37035904) (← links)
• Current and future therapeutic approaches in progressive supranuclear palsy (Q37217972) (← links)
• Therapy and clinical trials in frontotemporal dementia: past, present, and future (Q37566888) (← links)
• Visual signs and symptoms of progressive supranuclear palsy (Q37772535) (← links)
• Cholinesterase inhibitors: beyond Alzheimer’s disease (Q37806711) (← links)
• Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology (Q37810697) (← links)
• Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses. (Q37978747) (← links)
• New horizons in the pathogenesis, assessment and management of movement disorders. (Q38036239) (← links)
• Neuropsychiatry of corticobasal degeneration and progressive supranuclear palsy (Q38101088) (← links)
• Clinical trials: past, current, and future for atypical Parkinsonian syndromes (Q38223118) (← links)
• Are there treatments for atypical parkinsonism? An update on actual options (Q38534263) (← links)
• A Review of Treatment Options for Progressive Supranuclear Palsy (Q38843694) (← links)
• Managing cognition in progressive supranuclear palsy. (Q39017916) (← links)
• Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale (Q39669156) (← links)
• Progressive supranuclear palsy combined with Alzheimer's disease: a clinicopathological study of two autopsy cases (Q42444545) (← links)
• Cholinergic imaging in corticobasal syndrome, progressive supranuclear palsy and frontotemporal dementia (Q42473091) (← links)
• Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy (Q44969946) (← links)
• EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. (Q45289583) (← links)
• Emerging Diagnostic and Therapeutic Strategies for Tauopathies (Q45870549) (← links)
• Treatment of progressive supranuclear palsy and corticobasal degeneration (Q46643607) (← links)
• Neurotransmitter deficits from frontotemporal lobar degeneration (Q47837913) (← links)
• Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy (Q48153481) (← links)
• Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration (Q48529282) (← links)
• A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy (Q50479057) (← links)
• Treatment options for tauopathies. (Q53326015) (← links)
• Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior (Q58749782) (← links)
• Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies (Q62633604) (← links)
• [Medical management of patients with atypical degenerative parkinsonian syndromes] (Q79331113) (← links)
• [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors] (Q80769369) (← links)
• Progressive supranuclear palsy: living environment of the patients in Germany (Q84612979) (← links)
• Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism (Q90552481) (← links)
• Development of disease-modifying drugs for frontotemporal dementia spectrum disorders (Q90591149) (← links)